The manufacturer of the quadrivalent meningococcal polysaccharide-protein conjugate vaccine (MCV4, Menactra) reports that the vaccine no longer is in short supply. Therefore, the Academy and the Centers for Disease Control and Prevention (CDC) are recommending that clinicians resume routine vaccination of all groups for whom the vaccine is recommended.

In addition, a CDC study of cases of Guillain-Barré syndrome (GBS)among MCV4 recipients could not determine with certainty whether MCV4 increases the risk for GBS. Because invasive meningococcal disease causes significant morbidity and mortality, the Academy and the CDC's Advisory Committee on Immunization Practices (ACIP) continue to recommend administration of MCV4.

Menactra (manufactured by sanofi pasteur, Swiftwater, Pa.) was licensed for use among persons ages 11-55 years in January 2005.

In May 2005, the Academy and ACIP recommended routine vaccination with MCV4 for 11- to 12-year-olds, adolescents entering high school (those approximately 15 years old) if not previously vaccinated with MCV4,...

You do not currently have access to this content.